CA2299627A1 - Novel lactic acid bacteria - Google Patents
Novel lactic acid bacteria Download PDFInfo
- Publication number
- CA2299627A1 CA2299627A1 CA002299627A CA2299627A CA2299627A1 CA 2299627 A1 CA2299627 A1 CA 2299627A1 CA 002299627 A CA002299627 A CA 002299627A CA 2299627 A CA2299627 A CA 2299627A CA 2299627 A1 CA2299627 A1 CA 2299627A1
- Authority
- CA
- Canada
- Prior art keywords
- spp
- lactic acid
- bacteria
- plaque
- acid bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/363—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C15/00—Butter; Butter preparations; Making thereof
- A23C15/12—Butter preparations
- A23C15/123—Addition of microorganisms or cultured milk products; Addition of enzymes; Addition of starter cultures other than destillates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
- A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/366—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Abstract
Enterococcus spp. 1357, Lactobacillus spp. V20 and Lactococcus spp. 1370, and H2O2-producing Streptococci have a potent and lasting inhibitory activity on the production of water-insoluble glucan (mutan) and dental plaque in human mouth, or the growth of anaerobic bacteria causing gingivitis, periodontitis, and accompanied halitosis.
Description
WO 99/0?826 PCT/KR98/00191 NOVEL ?~ACTIC ACID BACTERIA
BACKGROUND OF THEM INVENTION
1. Field of the Invention The present invention relates to some novel lactic acid bacteria which inhibit the production of dental plaque in human mouths. More specifically, the production of water-insoluble glucan (mutan), a major component of dental plaque, which is produced by bacteria normally inhibiting in human mouths, can be inhibited by the novel bacteria. Oral anaerobic bacteria causing gingivitis, periodontitis, and accompanied halitosis (malodor) can be inhibited by the novel bacteria, too. These lactic acid bacteria belong to Enterococcus spp., Lactobacillus spp., Lactococcus spp., and Stretococcus spp. which inhibit the production of water-insoluble glucan or antagonize against the bacteria playing a role in forming water-insoluble glucan, or inhibit the growth of anaerobic bacteria causing gingivitis and periodontitis.
BACKGROUND OF THEM INVENTION
1. Field of the Invention The present invention relates to some novel lactic acid bacteria which inhibit the production of dental plaque in human mouths. More specifically, the production of water-insoluble glucan (mutan), a major component of dental plaque, which is produced by bacteria normally inhibiting in human mouths, can be inhibited by the novel bacteria. Oral anaerobic bacteria causing gingivitis, periodontitis, and accompanied halitosis (malodor) can be inhibited by the novel bacteria, too. These lactic acid bacteria belong to Enterococcus spp., Lactobacillus spp., Lactococcus spp., and Stretococcus spp. which inhibit the production of water-insoluble glucan or antagonize against the bacteria playing a role in forming water-insoluble glucan, or inhibit the growth of anaerobic bacteria causing gingivitis and periodontitis.
2. Description of the Prior Art Lactic acid bacteria generally ferment carbohydrates to lactic acid. Lactic acid bacteria live in the oral cavities and the alimentary tracts of men and animals and are utilized for the manufacture of fermentative foods, such as yogurt, cheese, etc. In addition, they are used for the production of biologically active materials, such as medicines. Representatives of these lactic acid-producing bacteria are Streptococcus thermophilus, Enterococcus faecalis, Enterococcus durans, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, and Lactobacillus plantarum. As inhabitants in the entrails of men and animals, these Gram-positive lactic acid bacteria are known to play an important role in maintaining the entrails healthy by the production of lactic acid and antibacterial materials which inhibit the growth of pathogenic bacteria.
The most important component of dental plaque is glucan. Glucan is either water-soluble glucan, dextran having 1,6-a linkage as a predominant linkage, or water-insoluble glucan (mutan) having 1,3-a linkage as a predominant linkage. The solubility in water is inversely proportional to the number of 1,3-a linkage. Therefore, water-insoluble glucan (mutan) serves as a main matrix of dental plaque. Dextranase (a-1,6 glucan hydrolase) which digests dextran, was tested as to its ability to prevent dental plaque. But the effectiveness value of dextranse to prevent dental plaque was questionable (Essential Dental Microbiology: Appleton & Lange, Norwalk, San Mateo, p.337, 1991), because dextranase can not digest mutan, the main matrix of dental plaque. Mutanase (endo-a-1,3-glucanase) which decomposes mutan was found to have some effect on the digestion of dental plaque. The decomposition effect of the mutanase on dental plaque, however, was trivial and it took too much time to express its effectivity. Therefore, these enzymes were found to have an insignificant effect on dental plaque formation in human oral cavity.
With regard to dental plaque prevention with lactic acid bacteria, European patent publication number 0-524-732-A2 disclosed the use of Streptococcus salivarius which was capable of extracellular production of dextranase. But its effect on preventing dental plaque is questionable because dextranase can not digest mutan, the main matrix of dental plaque. Streptococcus salivarius is not used as the starter bacteria fermenting milk.
i5 SUMMARY 0~' THE INVF,,N~ION
As a consequence of intensive and thorough researches on the inhibitory activity of lactic acid bacteria against the production of water-insoluble glucan or dental plaque and the growth of anaerobic bacteria, the present study has been based on the presumption that some lactic acid bacteria inhabiting in human mouths may be able to inhibit the production of water-insoluble glucan or dental plaque or the growth of anaerobic bacteria causing gingivitis and periodontitis. Through many clinical experiments, these novel strains have been found and proved to have the ability to inhibit the production of water-insoluble glucan or dental plaque significantly, and to inhibit the growth of anaerobic bacteria causing gingivitis and periodontitis.
They was named Enterococcus spp. 1357, Lactobacillus spp.
V20, and Lactococcus spp. 1370, respectively. They are now deposited in the Korean Collection for Type Cultures, Korean Research Institute of Bioscience and Biotechnology, on 30, Jul. and 11, Dec. 1997 (deposition No. KCTC 0360BP for Enterococcus spp. 1357, KCTC 0361BP for Lactobacillus spp.
V20, KCTC 0415BP for Lactococcus spp. 1370).
Glucan is either water-soluble or water-insoluble (mutan), each being synthesized from sucrose by the glucosyltransferase secreted from Streptococcus mutans, the most important bacteria among dental plaque-forming bacteria. However, only the water-insoluble glucan, mutan, is the main matrix of dental plaque.
Enterococcus spp. 1357, Lactobacillus spp. V20, and H20z-producing Streptococci such as Streptococcus oralis, Streptococcus mitior, Streptococcus mitis, and Streptococcus sanguis (Bergey's Manual of Systematic Bacteriology vol. 2:
Williams & Wilkins, Baltimore, London, Los Angeles, Sydney, 1986) have a growth-inhibitory activity on Streptococcus mutans. When.Streptococcus mutans was cultured with Enterococcus spp. 1357, Lactobacillus spp. V20, or Streptococcus oralis (ATCC 35037) as a representative of H202-producing Streptococci in the broth, the colony-forming number of Streptococcus mutans was decreased to about one hundredth compared with that of Streptococcus mutans alone.
The production of water-insoluble glucan or dental plaque was also suppressed significantly due to inhibition of Streptococcus mutans.
When high molecular weight dextran was added into the culture broth of Streptococcus mutans, the glucosyltransferase binding to water-insoluble glucan was interfered, and then the following synthesis of water-insoluble glucan was inhibited (Shigeyuki H., et al., Journal of General Microbiology, 116:51, 1980). Lactococcus spp. 1370 produced the large amounts of water-soluble glucan~ when Streptococcus mutans was incubated with this Lactococcus spp. 1370, the synthesis of water-insoluble glucan was suppressed.
Generally, dental plaque, adherent to the surface of teeth, provides a suitable habitat at which Streptococcus mutans as well as other bacteria proliferate and causes the dental caries formed, and it was an object of the present study to find novel bacteria which could inhibit the production of water-insoluble glucan or dental plaque by Streptococcus mutans in the mouth.
Anaerobic bacteria occur in high proportions in periodontitis as well as gingivitis of oral cavities. The proportions of anaerobic bacteria increase significantly (above 905 of microflora in periodontitis lesion) with increasing severity of the diseases. Predominant anaerobic bacteria causing gingivitis are Prevotella intermedia and Fusobacterium nucleatum. Predominant anaerobic bacteria causing periodontitis include Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, Prevotella intermedia, and Fusobacterium nucleatum (Contemporary Oral Microbiology and Immunology, Mosby-Year Book, St. Louis, 1992). These anaerobic bacteria produce malodorous components such as volatile sulfur compounds in mouth. The predominant volatile sulfur compounds are hydrogen sulfide from L-cysteine and methyl mercaptan from L-methionine (Persson, S., Oral Microbiol Immunol, 7:378, 1992). Lactobacillus spp. V20 and HZOz-producing Streptococci such as Streptococcus oralis, Streptococcus mitior, Streptococcus mitis, and Streptococcus sanguis produce hydrogen peroxide inhibiting the growth of anaerobic bacteria causing gingivitis and periodontitis, so improving and preventing the lesions, and decreasing the accompanied halitosis. The hydrogen peroxide is an oxidizing agent inactivating enzymes by converting functional -SH groups to the oxidized S-S form and is used as a disinfectant against bacteria, especially anaerobics.
Another object of this research was to provide foods or beverages employing the lactic acid bacteria. When the foods containing the lactic acid bacteria capable of directly inhibiting the production of water-insoluble glucan or having the growth-inhibitory activity on the microorganisms which contribute to the formation of dental plaque are eaten, the lactic acid bacteria naturally suppress the formation of dental plaque and consequently prevent dental caries formation. And when the foods contain the lactic acid bacteria capable of inhibiting the growth of anaerobic bacteria causing gingivitis and periodontitis, the lactic acid bacteria naturally improve and prevent gingivititis, periodontitis, and accompanied halitosis.
$RIEF DESCRIPTION OF THE DRAWING
Above and other objects and aspects of the invention will become apparent from the following description of embodiment with reference to the accompanying drawing which shows the inhibitory effect of the novel strain on the production of artificial dental plaque on orthodontic wires (Fig. 1) .
p~ETATLED DESCRIPTTON OF PROCESS TO THE INVE'~TTON
Lactic acid bacteria were taken from human bodies, streaked on Brain Heart Infusion agar, and cultured at 37°C.
*rB
_g_ Thereafter, separated bacterial colonies were tested whether they could suppress the production of the water-insoluble glucan that Streptococcus mutans (Ingbritt strain) produced.
In a cuvette, 3 mL of a Brain Heart Infusion medium supplemented with 0.5% yeast extract and 5o sucrose was inoculated with 0.1 mL of Streptococcus mutans and 0.1 mL of a culture broth of the separated bacteria. As a control, Streptococcus mutans was inoculated alone in a Brain Heart Infusion medium containing yeast extract and sucrose. The cuvette was placed at an angle of 30° to the horizontal plane of an incubator and incubated for 1 day at 37°C, in order for the Streptococcus mutans to produce water-insoluble glucan. After removing the culture broth, the cuvette was washed with 4 mL of distilled water and then, filled with 3 mL of distilled water. Its absorbance (OD) at 550 nm was measured by a spectrophotometer. Because the OD
value was proportional to the water-insoluble glucan produced, the bacteria which brought about a significantly lower OD value compared with the control, were isolated as dental plaque-inhibitory strains.
To evaluate the capability producing hydrogen peroxide, the isolated strains were streaked on the Brain Heart Infusion agar containing 0.25mg/mL 3,3',5,5'-tetramethylbenzidine dihydrochloride and 0.01mg/mL
horseradish peroxidase and incubated in anaerobic incubator for 48 hours. Lactobacillus spp. V20 formed the blue colonies, indicating that Lactobacillus spp. V20 had the capability to produce hydrogen peroxide.
The microbiological properties of the isolated strains, such as morphological and physiological properties (Table 1), and sugar catabolytic ability (Table 1) were investigated.
Morphological and Physiological Properties Isolated Bacterial Strains Pro erties p Enterococcus Lactobacillus Lactobacillus spp. 1357 spp. V20 spp. 1370 Morphology coccus, bacillus, coccus, chain chain chain Gram stain positive positive positive Spore forming - - -Catalase - - -Activity Culture + - +
Temp. 10C
Culture + + -Temp. 45C
pH 9 . 6 + - -1~ 40 bile acid + - +
6.5% NaCl + - -Growth on MRS - + -medium Acetoin + +
Production Hippurate + -Hydrolysis Pyrrolidonylary + -amidase a- - -Galactosidase o nidase Glucu o sidase Galac Alkaline - -phosphatase Leucine + +
arylamidase 3J A r ; nine + _ d i by rolase Catalytic Activities on Sugars Carbohydrate Isolated Bacterial Strains Enterococcus Lactobacillus Lactococcus spp. 1357 spp. V20 spp. 13i0 Arabinose - - -Amygdalin + - -Cellobiose + + +
Esculin + + -Fructose + + +
Galactose + + +
Glucose + + +
Lactose + + +
Maltose + + +
Mannitol - - +
Mannose + + +
I~ Melezitose - - -Raffinose - - -Rhamnose - - -Salicin + - -Sorbitol - - -Trehalose + + +
Inulin - -Starch + +
Glycogen - -As mentioned above, the novel lactic acid bacteria being able t;, inhibit the production of dental plaque were isolated and assayed in comparison with the control in vitro. Further, the novel properties were tested in vivo, that is, the isolated novel bacteria were applied to the human oral cavity.
EXAMPLE I
Inhibition of the Production of Water-Insoluble Glucan in Disposable Cuvette An equal amount of M17 medium was mixed with MRS medium and supplemented with 0.5% yeast extract, 5% sucrose and O.1M TES (pH 8.0). Three milliliters of the constituted medium were transferred to a disposable cuvette which was, then, inoculated with 751 of Streptococcus mutans overnight culture. The cuvette was placed at an angle of 30° to the horizontal plane in an incubator and cultured at 30°C for 1 day. The content was removed and then, the cuvette was washed with 3mL of distilled water. Thereafter, the cuvette was filled with 4mL of distilled water and the absorbency at 550nm was measured by a spectrophotometer. This measurement was repeated three times and the average value was obtained (Table 3) .
Inhibitory Effect of Lactic Acid Bacteria on the Production of Water-Insoluble Glucan Samples Test Bacterial Strains OD (550nm) Control I Str. mutans 2.122 Control II Streptococcus thermophilus 2.325 + Str. mutans Group I Enterococcus spp. 1357 0.434 Group II Enterococcus spp. 1357 0.713 + Str. mutans Group III Lactobacillus spp. V20 0.506 Group IV Lactobacillus spp. V20 1.154 + Str. mutans Group V Lactococcus spp. 1370 0.576 Group VI Lactococcus spp. 1370 1.020 + Str. mutans Group VII Streptococcus oralis 0.511 Group VIII Streptococcus oralis 0.980 + Str. mutans As shown in Table 3, the optical densities of Control group I and Control group II were 2.122 and 2.325 in absorbency at 550nm whereas those of Test group II, Test group IV, Test group VI, and Test group VIII were 0.713, 1.154, 1.020, and 0.980, respectively. This reduction in the absorbency meant that these bacteria inhibited the Streptococcus mutans' production of water-insoluble glucan.
EXAMPLE II
Artificial Dental Plaque Formation on Orthodontic Wire An equal amount of M17 medium was mixed with MRS medium and supplemented with 0.5~ yeast extract, 5~S sucrose,- and O.1M TES (pH 8.0). One hundred and fifty milliliters of the constituted medium were poured into beaker. 0.016 inch stainless steel orthodontic wires (45mg) were immersed in the medium. Streptococcus mutans was inoculated at the concentration of 2.5X106 per mL of the medium. Thereafter, the lactic acid bacterial strains were inoculated in the medium at the concentration of 5 times higher than that of Streptococcus mutans and incubated in a COZ incubator at 37°C for 6.5 hours with shaking. Only water-insoluble glucan or plaque was attached on the wires (McCabe, R.M., et. Al., Archs oral Boil., 12:1653, 1967). The wires were transferred to fresh beakers and photographed (Fig. 1).
Fig. 1(A) is a photograph of the culture of Streptococcus mutans alone while Fig. 1(B) is that of the co-culture of Streptococcus mutans and Lactococcus spp. 1370.
The weights of the artificial plaques formed on the wires were measured and the results are shown in Table 4.
Inhibitory Activity of Lactic Acid Bacteria on the Formation of Artificial Plaque Samples Test Bacterial Strains Weight of Produced Plaque Control I Str. mutans 75.4 mg Control II Streptococcus thermophilus 92.3 mg + Str. mutans Group I Enterococcus spp. 1357 0.0 mg + Str. mutans Group II Lactobacillus spp. V20 30.9 mg + Str, mutans Group III Lactococcus spp. 1370 0.0 mg + Str. mutans Group IV Streptococcus oralis 0.0 mg + Str. mutans In the control group I and the control group II, an artificial plaque of 75.4 mg and 92.3 mg was formed while no artificial plaque was formed in Test group I, Test group III
and Test group IV. In Test group II, the plaque weight was reduced to 30.9 mg. Thus, it is clearly shown that these bacteria have a potent inhibitory activity on the production of dental plaque by Streptococcus mutans.
EXAMPLE III
Reduction of the Dental Plaque Index in Human Mouths In order to evaluate the reduction effect of the novel lactic acid bacterial strains on plaque index in human mouths, experiments were performed in thirty-eight persons to achieve the plaque scores by Quigley and Hein Plaque S Index (Harper, D.S., et. Al., J Periodontol, 61:352, 1990).
Thirty-eight young adults, 22 to 26 years of age, volunteered to participate in this study. All volunteers were received thorough oral prophylaxis, and suspended all oral hygiene. Volunteers ate and drank as usual, but stopped brush washing. Baseline plaque scores were assessed at 24 hours after receiving oral prophylaxis. Plaque scores were performed by Quigley and Hein Plaque Index after disclosing all plaque except third molars. The volunteers were randomly assigned to two groups (each nineteen persons), group I mouthrinsing with Lactococcus spp. 1370 while group II mouthrinsing with Lactobacillus spp. V20.
Test bacterial suspensions were prepared by incubating either Lactococcus spp. 1370 or Lactobacillus spp. V20 in milk for 24 hours. Volunteers rinsed immediately once after oral prophylaxis and twice after meals with 20 mL of Lactococcus spp. 1370 or Lactobacillus spp. V20 culture in milk (109 CFU/mL) for 2 minutes. Plaque scores were again assessed at 24 hours after receiving oral prophylaxis. The plaque scores of total teeth except third molars were averaged and statistically analyzed in each group. The results indicated that plaque index reduction of 0.97 in the group I and 0.55 in the group II at 24 hours after receiving oral prophylaxis (Table 5). The reductions of plaque index were statistically significant (p<0.05), i.e. Lactococcus sp. 1370 and Lactobacillus sp. V20 reduced plaque formation in the oral cavity significantly.
Reduction of the Plaque Index by Bacterial Mouthrinse Mean Mean Plaque Score Used Bacteria Baseline afer Bacterial Difference Plaque Score Mouthrinse Lactococcus 2.17 1.20 -0.97*
spp. 1370 Lactobacillus 2.15 1.60 -0.55*
spp. V20 p« .ul py pairea z zest EXAMPLE IV
Inhibition of the Growth of Anaerobic Bacteria in Mixed Culture Lactobacillus spp. V20 was cultured in MRS media for 24 hours. Prophyromonas gingivalis, Prevotella intermedia, and Fusobacterium nucleatum were cultured in the anaerobic bacteria culture broth containing Brain Heart Infusion media 18.5 g, yeast extract 5.0 g, hemin solution 10 mL (dissolved 50 mg hemin in 1 N sodium hydroxy solution 1 mL and added with distilled water 100 mL), and vitamin K solution 0.2 mL
(vitamin K solution 0.15 mL mixed with 95°s ethanol 30 mL) per liter in anaerobic incubator for 36 hours.
Actinobacillus actinomycetemcomitans was cultured in the TSBV media containing Tryptic soy broth 30 g, yeast extract 1.0 g, horse serum 100 mL, bacitracin 75 mg, and vancomycin 5 mg per liter in anaerobic incubator for 36 hours. Culture suspension 0.1 mL of Lactobacillus spp. V20 and each anaerobic bacterium at the concentration of 1.4X108 per mL
were inoculated singly or in combination in the media containing anaerobic bacteria culture broth or TSBV media 3.7 mL mixed with MRS broth 0.3 mL, and cultured in anaerobic incubator for 36 hours. The culture suspension was diluted and inoculated on MRS agar, anaerobic bacteria culture agar containing 3o sheep blood or TSBV agar. At 72 hours after culturing, the number of colonies was counted.
The colony-forming units of Lactobacillus spp. V20 and each anaerobic bacterium were increased after being cultured singly, whereas the colony of each anaerobic bacterium was not found after being cultured in combination with Lactobacillus spp. V20. When anaerobic bacteria was cultured with Lactobacillus casei which did not produce hydrogen peroxide, the colony-forming units were not decreased significantly (Table 5). When Streptococcus oralis (ATCC 35037) as a representative of H202-producing Streptococci was cultured with each anaerobic bacterium by the above mentioned method, anaerobic bacteria did not form a colony on the media.
Colony-forming Units after Culturing Colony-forming Colony-forming Inoculated units of units of bacteria Lactobac illus anaerobe after after culture(/mL) culture (/mL) Lactobacillus spp. 8.2 X 108 Lactobacillus casei 9.0 X 108 Porphyromonas 1.9 X lOg gingivalis Actinobacillus 2.0 X 108 actinomycetemcomitans Prevotella intermedia 1.8 X 108 Fusobacterium 1.8 X 10$
nucleatum Lactobacillus spp.
V20 + Porphyromonas 8.0 X 108 0 gingivalis Lactobacillus spp.
V20 + Actinobacillus 8.8 X I08 0 actinomycetemcomitans Lactobacillus spp.
V20 + Prevotella 8.9 X 108 0 intermedia Lactobacillus spp.
V20 + Fusobacterium 7.8 X 108 0 nucleatum Lactobacillus casei +
Porphyromonas 9.1 X 108 1.5 X 108 gingivalis Lactobacillus casei +
Actinobacillus 9.3 X 108 I.8 X 108 actinomycetemcomitans Lactobacillus casei 8.9 X 108 1.6 X 108 +
Prevotella intermedia Lactobacillus casei +
Fusobacterium 9.8 X 108 1.6 X 10g nucleatum *rB
Hereafter were presented the examples in which the novel lactic acid bacteria were practically applied.
USE EXAMPLE I: Yogurt A broth culture containing the novel lactic acid bacterial strains was added at an amount of 0.1 vol. percent to the food just before fermentation and subjected to fermentation along with the existing bacteria to produce yogurt foods. The resulting yogurt foods were tasted by 10 panelists. They noted no different flavor between the test samples and the commercially available foods (controls).
Before a sealing step in the manufacture procedure, the lactic acid bacterial strains were added at an amount of 0.2 vol. percent. A response that these test samples thus obtained were not different from the control foods in taste was drawn from 10 panelists who took part in the tasting tests.
USE EXAMPLE II: Butter Before a packaging step, butter foods which were manufactured by a typical procedure were added with 0.2 wt.
percent of the freeze-dried lactic acid bacterial strains.
These butter foods thus obtained were given as taste samples.
USE EXAMPLE III: Cheese Before a packaging step, cheese foods which were manufactured by a typical procedure were added with 0.2 wt.
percent of the freeze-dried lactic acid bacterial strains.
These cheese foods thus obtained were given as taste samples.
USE EXAMPLE IV: Freeze-dried lactic acid bacteria The novel lactic acid bacteria were cultured and freeze-dried (lyophilized). These freeze-dried bacteria in capsule', tablet, and small package could be taken singly or with other bacteria or materials. These freeze-dried products thus obtained were given taste samples.
Accordingly, the lactic acid bacterial strains were applied for various foods, including gum, shortening, ice cream, margarine, kimchi, etc.
From the examples above, it is apparent that the novel lactic acid strains have a potent and lasting inhibitory effect on the production of water-insoluble glucan or dental WO 99/07826 PCT/KR9$/OOi91 plaque in human mouth, or on the growth of anaerobic bacteria causing gingivitis, periodontitis, and accompanied halitosis.
In addition, the novel strains were found to be able to be applied for various foods as well as directly to the teeth.
Many modifications and variations of the present invention are possible in the light of the above techniques.
The most important component of dental plaque is glucan. Glucan is either water-soluble glucan, dextran having 1,6-a linkage as a predominant linkage, or water-insoluble glucan (mutan) having 1,3-a linkage as a predominant linkage. The solubility in water is inversely proportional to the number of 1,3-a linkage. Therefore, water-insoluble glucan (mutan) serves as a main matrix of dental plaque. Dextranase (a-1,6 glucan hydrolase) which digests dextran, was tested as to its ability to prevent dental plaque. But the effectiveness value of dextranse to prevent dental plaque was questionable (Essential Dental Microbiology: Appleton & Lange, Norwalk, San Mateo, p.337, 1991), because dextranase can not digest mutan, the main matrix of dental plaque. Mutanase (endo-a-1,3-glucanase) which decomposes mutan was found to have some effect on the digestion of dental plaque. The decomposition effect of the mutanase on dental plaque, however, was trivial and it took too much time to express its effectivity. Therefore, these enzymes were found to have an insignificant effect on dental plaque formation in human oral cavity.
With regard to dental plaque prevention with lactic acid bacteria, European patent publication number 0-524-732-A2 disclosed the use of Streptococcus salivarius which was capable of extracellular production of dextranase. But its effect on preventing dental plaque is questionable because dextranase can not digest mutan, the main matrix of dental plaque. Streptococcus salivarius is not used as the starter bacteria fermenting milk.
i5 SUMMARY 0~' THE INVF,,N~ION
As a consequence of intensive and thorough researches on the inhibitory activity of lactic acid bacteria against the production of water-insoluble glucan or dental plaque and the growth of anaerobic bacteria, the present study has been based on the presumption that some lactic acid bacteria inhabiting in human mouths may be able to inhibit the production of water-insoluble glucan or dental plaque or the growth of anaerobic bacteria causing gingivitis and periodontitis. Through many clinical experiments, these novel strains have been found and proved to have the ability to inhibit the production of water-insoluble glucan or dental plaque significantly, and to inhibit the growth of anaerobic bacteria causing gingivitis and periodontitis.
They was named Enterococcus spp. 1357, Lactobacillus spp.
V20, and Lactococcus spp. 1370, respectively. They are now deposited in the Korean Collection for Type Cultures, Korean Research Institute of Bioscience and Biotechnology, on 30, Jul. and 11, Dec. 1997 (deposition No. KCTC 0360BP for Enterococcus spp. 1357, KCTC 0361BP for Lactobacillus spp.
V20, KCTC 0415BP for Lactococcus spp. 1370).
Glucan is either water-soluble or water-insoluble (mutan), each being synthesized from sucrose by the glucosyltransferase secreted from Streptococcus mutans, the most important bacteria among dental plaque-forming bacteria. However, only the water-insoluble glucan, mutan, is the main matrix of dental plaque.
Enterococcus spp. 1357, Lactobacillus spp. V20, and H20z-producing Streptococci such as Streptococcus oralis, Streptococcus mitior, Streptococcus mitis, and Streptococcus sanguis (Bergey's Manual of Systematic Bacteriology vol. 2:
Williams & Wilkins, Baltimore, London, Los Angeles, Sydney, 1986) have a growth-inhibitory activity on Streptococcus mutans. When.Streptococcus mutans was cultured with Enterococcus spp. 1357, Lactobacillus spp. V20, or Streptococcus oralis (ATCC 35037) as a representative of H202-producing Streptococci in the broth, the colony-forming number of Streptococcus mutans was decreased to about one hundredth compared with that of Streptococcus mutans alone.
The production of water-insoluble glucan or dental plaque was also suppressed significantly due to inhibition of Streptococcus mutans.
When high molecular weight dextran was added into the culture broth of Streptococcus mutans, the glucosyltransferase binding to water-insoluble glucan was interfered, and then the following synthesis of water-insoluble glucan was inhibited (Shigeyuki H., et al., Journal of General Microbiology, 116:51, 1980). Lactococcus spp. 1370 produced the large amounts of water-soluble glucan~ when Streptococcus mutans was incubated with this Lactococcus spp. 1370, the synthesis of water-insoluble glucan was suppressed.
Generally, dental plaque, adherent to the surface of teeth, provides a suitable habitat at which Streptococcus mutans as well as other bacteria proliferate and causes the dental caries formed, and it was an object of the present study to find novel bacteria which could inhibit the production of water-insoluble glucan or dental plaque by Streptococcus mutans in the mouth.
Anaerobic bacteria occur in high proportions in periodontitis as well as gingivitis of oral cavities. The proportions of anaerobic bacteria increase significantly (above 905 of microflora in periodontitis lesion) with increasing severity of the diseases. Predominant anaerobic bacteria causing gingivitis are Prevotella intermedia and Fusobacterium nucleatum. Predominant anaerobic bacteria causing periodontitis include Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, Prevotella intermedia, and Fusobacterium nucleatum (Contemporary Oral Microbiology and Immunology, Mosby-Year Book, St. Louis, 1992). These anaerobic bacteria produce malodorous components such as volatile sulfur compounds in mouth. The predominant volatile sulfur compounds are hydrogen sulfide from L-cysteine and methyl mercaptan from L-methionine (Persson, S., Oral Microbiol Immunol, 7:378, 1992). Lactobacillus spp. V20 and HZOz-producing Streptococci such as Streptococcus oralis, Streptococcus mitior, Streptococcus mitis, and Streptococcus sanguis produce hydrogen peroxide inhibiting the growth of anaerobic bacteria causing gingivitis and periodontitis, so improving and preventing the lesions, and decreasing the accompanied halitosis. The hydrogen peroxide is an oxidizing agent inactivating enzymes by converting functional -SH groups to the oxidized S-S form and is used as a disinfectant against bacteria, especially anaerobics.
Another object of this research was to provide foods or beverages employing the lactic acid bacteria. When the foods containing the lactic acid bacteria capable of directly inhibiting the production of water-insoluble glucan or having the growth-inhibitory activity on the microorganisms which contribute to the formation of dental plaque are eaten, the lactic acid bacteria naturally suppress the formation of dental plaque and consequently prevent dental caries formation. And when the foods contain the lactic acid bacteria capable of inhibiting the growth of anaerobic bacteria causing gingivitis and periodontitis, the lactic acid bacteria naturally improve and prevent gingivititis, periodontitis, and accompanied halitosis.
$RIEF DESCRIPTION OF THE DRAWING
Above and other objects and aspects of the invention will become apparent from the following description of embodiment with reference to the accompanying drawing which shows the inhibitory effect of the novel strain on the production of artificial dental plaque on orthodontic wires (Fig. 1) .
p~ETATLED DESCRIPTTON OF PROCESS TO THE INVE'~TTON
Lactic acid bacteria were taken from human bodies, streaked on Brain Heart Infusion agar, and cultured at 37°C.
*rB
_g_ Thereafter, separated bacterial colonies were tested whether they could suppress the production of the water-insoluble glucan that Streptococcus mutans (Ingbritt strain) produced.
In a cuvette, 3 mL of a Brain Heart Infusion medium supplemented with 0.5% yeast extract and 5o sucrose was inoculated with 0.1 mL of Streptococcus mutans and 0.1 mL of a culture broth of the separated bacteria. As a control, Streptococcus mutans was inoculated alone in a Brain Heart Infusion medium containing yeast extract and sucrose. The cuvette was placed at an angle of 30° to the horizontal plane of an incubator and incubated for 1 day at 37°C, in order for the Streptococcus mutans to produce water-insoluble glucan. After removing the culture broth, the cuvette was washed with 4 mL of distilled water and then, filled with 3 mL of distilled water. Its absorbance (OD) at 550 nm was measured by a spectrophotometer. Because the OD
value was proportional to the water-insoluble glucan produced, the bacteria which brought about a significantly lower OD value compared with the control, were isolated as dental plaque-inhibitory strains.
To evaluate the capability producing hydrogen peroxide, the isolated strains were streaked on the Brain Heart Infusion agar containing 0.25mg/mL 3,3',5,5'-tetramethylbenzidine dihydrochloride and 0.01mg/mL
horseradish peroxidase and incubated in anaerobic incubator for 48 hours. Lactobacillus spp. V20 formed the blue colonies, indicating that Lactobacillus spp. V20 had the capability to produce hydrogen peroxide.
The microbiological properties of the isolated strains, such as morphological and physiological properties (Table 1), and sugar catabolytic ability (Table 1) were investigated.
Morphological and Physiological Properties Isolated Bacterial Strains Pro erties p Enterococcus Lactobacillus Lactobacillus spp. 1357 spp. V20 spp. 1370 Morphology coccus, bacillus, coccus, chain chain chain Gram stain positive positive positive Spore forming - - -Catalase - - -Activity Culture + - +
Temp. 10C
Culture + + -Temp. 45C
pH 9 . 6 + - -1~ 40 bile acid + - +
6.5% NaCl + - -Growth on MRS - + -medium Acetoin + +
Production Hippurate + -Hydrolysis Pyrrolidonylary + -amidase a- - -Galactosidase o nidase Glucu o sidase Galac Alkaline - -phosphatase Leucine + +
arylamidase 3J A r ; nine + _ d i by rolase Catalytic Activities on Sugars Carbohydrate Isolated Bacterial Strains Enterococcus Lactobacillus Lactococcus spp. 1357 spp. V20 spp. 13i0 Arabinose - - -Amygdalin + - -Cellobiose + + +
Esculin + + -Fructose + + +
Galactose + + +
Glucose + + +
Lactose + + +
Maltose + + +
Mannitol - - +
Mannose + + +
I~ Melezitose - - -Raffinose - - -Rhamnose - - -Salicin + - -Sorbitol - - -Trehalose + + +
Inulin - -Starch + +
Glycogen - -As mentioned above, the novel lactic acid bacteria being able t;, inhibit the production of dental plaque were isolated and assayed in comparison with the control in vitro. Further, the novel properties were tested in vivo, that is, the isolated novel bacteria were applied to the human oral cavity.
EXAMPLE I
Inhibition of the Production of Water-Insoluble Glucan in Disposable Cuvette An equal amount of M17 medium was mixed with MRS medium and supplemented with 0.5% yeast extract, 5% sucrose and O.1M TES (pH 8.0). Three milliliters of the constituted medium were transferred to a disposable cuvette which was, then, inoculated with 751 of Streptococcus mutans overnight culture. The cuvette was placed at an angle of 30° to the horizontal plane in an incubator and cultured at 30°C for 1 day. The content was removed and then, the cuvette was washed with 3mL of distilled water. Thereafter, the cuvette was filled with 4mL of distilled water and the absorbency at 550nm was measured by a spectrophotometer. This measurement was repeated three times and the average value was obtained (Table 3) .
Inhibitory Effect of Lactic Acid Bacteria on the Production of Water-Insoluble Glucan Samples Test Bacterial Strains OD (550nm) Control I Str. mutans 2.122 Control II Streptococcus thermophilus 2.325 + Str. mutans Group I Enterococcus spp. 1357 0.434 Group II Enterococcus spp. 1357 0.713 + Str. mutans Group III Lactobacillus spp. V20 0.506 Group IV Lactobacillus spp. V20 1.154 + Str. mutans Group V Lactococcus spp. 1370 0.576 Group VI Lactococcus spp. 1370 1.020 + Str. mutans Group VII Streptococcus oralis 0.511 Group VIII Streptococcus oralis 0.980 + Str. mutans As shown in Table 3, the optical densities of Control group I and Control group II were 2.122 and 2.325 in absorbency at 550nm whereas those of Test group II, Test group IV, Test group VI, and Test group VIII were 0.713, 1.154, 1.020, and 0.980, respectively. This reduction in the absorbency meant that these bacteria inhibited the Streptococcus mutans' production of water-insoluble glucan.
EXAMPLE II
Artificial Dental Plaque Formation on Orthodontic Wire An equal amount of M17 medium was mixed with MRS medium and supplemented with 0.5~ yeast extract, 5~S sucrose,- and O.1M TES (pH 8.0). One hundred and fifty milliliters of the constituted medium were poured into beaker. 0.016 inch stainless steel orthodontic wires (45mg) were immersed in the medium. Streptococcus mutans was inoculated at the concentration of 2.5X106 per mL of the medium. Thereafter, the lactic acid bacterial strains were inoculated in the medium at the concentration of 5 times higher than that of Streptococcus mutans and incubated in a COZ incubator at 37°C for 6.5 hours with shaking. Only water-insoluble glucan or plaque was attached on the wires (McCabe, R.M., et. Al., Archs oral Boil., 12:1653, 1967). The wires were transferred to fresh beakers and photographed (Fig. 1).
Fig. 1(A) is a photograph of the culture of Streptococcus mutans alone while Fig. 1(B) is that of the co-culture of Streptococcus mutans and Lactococcus spp. 1370.
The weights of the artificial plaques formed on the wires were measured and the results are shown in Table 4.
Inhibitory Activity of Lactic Acid Bacteria on the Formation of Artificial Plaque Samples Test Bacterial Strains Weight of Produced Plaque Control I Str. mutans 75.4 mg Control II Streptococcus thermophilus 92.3 mg + Str. mutans Group I Enterococcus spp. 1357 0.0 mg + Str. mutans Group II Lactobacillus spp. V20 30.9 mg + Str, mutans Group III Lactococcus spp. 1370 0.0 mg + Str. mutans Group IV Streptococcus oralis 0.0 mg + Str. mutans In the control group I and the control group II, an artificial plaque of 75.4 mg and 92.3 mg was formed while no artificial plaque was formed in Test group I, Test group III
and Test group IV. In Test group II, the plaque weight was reduced to 30.9 mg. Thus, it is clearly shown that these bacteria have a potent inhibitory activity on the production of dental plaque by Streptococcus mutans.
EXAMPLE III
Reduction of the Dental Plaque Index in Human Mouths In order to evaluate the reduction effect of the novel lactic acid bacterial strains on plaque index in human mouths, experiments were performed in thirty-eight persons to achieve the plaque scores by Quigley and Hein Plaque S Index (Harper, D.S., et. Al., J Periodontol, 61:352, 1990).
Thirty-eight young adults, 22 to 26 years of age, volunteered to participate in this study. All volunteers were received thorough oral prophylaxis, and suspended all oral hygiene. Volunteers ate and drank as usual, but stopped brush washing. Baseline plaque scores were assessed at 24 hours after receiving oral prophylaxis. Plaque scores were performed by Quigley and Hein Plaque Index after disclosing all plaque except third molars. The volunteers were randomly assigned to two groups (each nineteen persons), group I mouthrinsing with Lactococcus spp. 1370 while group II mouthrinsing with Lactobacillus spp. V20.
Test bacterial suspensions were prepared by incubating either Lactococcus spp. 1370 or Lactobacillus spp. V20 in milk for 24 hours. Volunteers rinsed immediately once after oral prophylaxis and twice after meals with 20 mL of Lactococcus spp. 1370 or Lactobacillus spp. V20 culture in milk (109 CFU/mL) for 2 minutes. Plaque scores were again assessed at 24 hours after receiving oral prophylaxis. The plaque scores of total teeth except third molars were averaged and statistically analyzed in each group. The results indicated that plaque index reduction of 0.97 in the group I and 0.55 in the group II at 24 hours after receiving oral prophylaxis (Table 5). The reductions of plaque index were statistically significant (p<0.05), i.e. Lactococcus sp. 1370 and Lactobacillus sp. V20 reduced plaque formation in the oral cavity significantly.
Reduction of the Plaque Index by Bacterial Mouthrinse Mean Mean Plaque Score Used Bacteria Baseline afer Bacterial Difference Plaque Score Mouthrinse Lactococcus 2.17 1.20 -0.97*
spp. 1370 Lactobacillus 2.15 1.60 -0.55*
spp. V20 p« .ul py pairea z zest EXAMPLE IV
Inhibition of the Growth of Anaerobic Bacteria in Mixed Culture Lactobacillus spp. V20 was cultured in MRS media for 24 hours. Prophyromonas gingivalis, Prevotella intermedia, and Fusobacterium nucleatum were cultured in the anaerobic bacteria culture broth containing Brain Heart Infusion media 18.5 g, yeast extract 5.0 g, hemin solution 10 mL (dissolved 50 mg hemin in 1 N sodium hydroxy solution 1 mL and added with distilled water 100 mL), and vitamin K solution 0.2 mL
(vitamin K solution 0.15 mL mixed with 95°s ethanol 30 mL) per liter in anaerobic incubator for 36 hours.
Actinobacillus actinomycetemcomitans was cultured in the TSBV media containing Tryptic soy broth 30 g, yeast extract 1.0 g, horse serum 100 mL, bacitracin 75 mg, and vancomycin 5 mg per liter in anaerobic incubator for 36 hours. Culture suspension 0.1 mL of Lactobacillus spp. V20 and each anaerobic bacterium at the concentration of 1.4X108 per mL
were inoculated singly or in combination in the media containing anaerobic bacteria culture broth or TSBV media 3.7 mL mixed with MRS broth 0.3 mL, and cultured in anaerobic incubator for 36 hours. The culture suspension was diluted and inoculated on MRS agar, anaerobic bacteria culture agar containing 3o sheep blood or TSBV agar. At 72 hours after culturing, the number of colonies was counted.
The colony-forming units of Lactobacillus spp. V20 and each anaerobic bacterium were increased after being cultured singly, whereas the colony of each anaerobic bacterium was not found after being cultured in combination with Lactobacillus spp. V20. When anaerobic bacteria was cultured with Lactobacillus casei which did not produce hydrogen peroxide, the colony-forming units were not decreased significantly (Table 5). When Streptococcus oralis (ATCC 35037) as a representative of H202-producing Streptococci was cultured with each anaerobic bacterium by the above mentioned method, anaerobic bacteria did not form a colony on the media.
Colony-forming Units after Culturing Colony-forming Colony-forming Inoculated units of units of bacteria Lactobac illus anaerobe after after culture(/mL) culture (/mL) Lactobacillus spp. 8.2 X 108 Lactobacillus casei 9.0 X 108 Porphyromonas 1.9 X lOg gingivalis Actinobacillus 2.0 X 108 actinomycetemcomitans Prevotella intermedia 1.8 X 108 Fusobacterium 1.8 X 10$
nucleatum Lactobacillus spp.
V20 + Porphyromonas 8.0 X 108 0 gingivalis Lactobacillus spp.
V20 + Actinobacillus 8.8 X I08 0 actinomycetemcomitans Lactobacillus spp.
V20 + Prevotella 8.9 X 108 0 intermedia Lactobacillus spp.
V20 + Fusobacterium 7.8 X 108 0 nucleatum Lactobacillus casei +
Porphyromonas 9.1 X 108 1.5 X 108 gingivalis Lactobacillus casei +
Actinobacillus 9.3 X 108 I.8 X 108 actinomycetemcomitans Lactobacillus casei 8.9 X 108 1.6 X 108 +
Prevotella intermedia Lactobacillus casei +
Fusobacterium 9.8 X 108 1.6 X 10g nucleatum *rB
Hereafter were presented the examples in which the novel lactic acid bacteria were practically applied.
USE EXAMPLE I: Yogurt A broth culture containing the novel lactic acid bacterial strains was added at an amount of 0.1 vol. percent to the food just before fermentation and subjected to fermentation along with the existing bacteria to produce yogurt foods. The resulting yogurt foods were tasted by 10 panelists. They noted no different flavor between the test samples and the commercially available foods (controls).
Before a sealing step in the manufacture procedure, the lactic acid bacterial strains were added at an amount of 0.2 vol. percent. A response that these test samples thus obtained were not different from the control foods in taste was drawn from 10 panelists who took part in the tasting tests.
USE EXAMPLE II: Butter Before a packaging step, butter foods which were manufactured by a typical procedure were added with 0.2 wt.
percent of the freeze-dried lactic acid bacterial strains.
These butter foods thus obtained were given as taste samples.
USE EXAMPLE III: Cheese Before a packaging step, cheese foods which were manufactured by a typical procedure were added with 0.2 wt.
percent of the freeze-dried lactic acid bacterial strains.
These cheese foods thus obtained were given as taste samples.
USE EXAMPLE IV: Freeze-dried lactic acid bacteria The novel lactic acid bacteria were cultured and freeze-dried (lyophilized). These freeze-dried bacteria in capsule', tablet, and small package could be taken singly or with other bacteria or materials. These freeze-dried products thus obtained were given taste samples.
Accordingly, the lactic acid bacterial strains were applied for various foods, including gum, shortening, ice cream, margarine, kimchi, etc.
From the examples above, it is apparent that the novel lactic acid strains have a potent and lasting inhibitory effect on the production of water-insoluble glucan or dental WO 99/07826 PCT/KR9$/OOi91 plaque in human mouth, or on the growth of anaerobic bacteria causing gingivitis, periodontitis, and accompanied halitosis.
In addition, the novel strains were found to be able to be applied for various foods as well as directly to the teeth.
Many modifications and variations of the present invention are possible in the light of the above techniques.
Claims (4)
1. Lactic acid bacteria which inhibit the production of water-insoluble glucan (mutan) or dental plaque by affecting the enzyme glucosyltransferase.
2. Lactic acid bacteria in accordance with claim 1 is Lactococcus spp. 1370 (KCTC 0415BP).
3. Lactic acid bacteria which produce hydrogen peroxide (H2O2) to inhibit the growth of anaerobic bacteria.
4. Lactic acid bacteria in accordance with claim 3 are Lactobacillus spp. V20 (KCTC 0361BP) and Streptococcus oralis (ATCC 35037).
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019970037819A KR19990024297A (en) | 1997-08-07 | 1997-08-07 | Novel Lactic Acid Bacteria Inhibit Plaque Formation in Human Oral cavity |
KR1997/37819 | 1997-08-07 | ||
KR19980000213A KR100266752B1 (en) | 1997-08-07 | 1998-01-07 | Plaque inhitition by novel human oral strains of lacticacid producing bacteria |
KR1998/213 | 1998-01-07 | ||
KR1998/19512 | 1998-05-28 | ||
KR1019980019512A KR19990086509A (en) | 1998-05-28 | 1998-05-28 | Lactobacillus inhibits anaerobic bacteria in human oral cavity |
PCT/KR1998/000191 WO1999007826A1 (en) | 1997-08-07 | 1998-07-02 | Novel lactic acid bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2299627A1 true CA2299627A1 (en) | 1999-02-18 |
Family
ID=27349588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002299627A Abandoned CA2299627A1 (en) | 1997-08-07 | 1998-07-02 | Novel lactic acid bacteria |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1002052A1 (en) |
JP (1) | JP2001512670A (en) |
KR (1) | KR100266752B1 (en) |
CN (1) | CN1268172A (en) |
AU (1) | AU752706B2 (en) |
BR (1) | BR9814737A (en) |
CA (1) | CA2299627A1 (en) |
IL (1) | IL134410A0 (en) |
MX (1) | MXPA00001347A (en) |
TR (1) | TR200000360T2 (en) |
WO (1) | WO1999007826A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL146179A0 (en) * | 1999-04-26 | 2002-07-25 | Innoscent Ltd | Method and kit for indicating the level of bad breath |
IT1306716B1 (en) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES. |
JP3921175B2 (en) * | 2001-04-02 | 2007-05-30 | わかもと製薬株式会社 | Composition for prevention and / or treatment of oral disease |
US7052614B2 (en) | 2001-08-06 | 2006-05-30 | A.Y. Laboratories Ltd. | Control of development of biofilms in industrial process water |
JP2003250493A (en) * | 2001-12-28 | 2003-09-09 | Toyo Shinyaku:Kk | Anticavity food comprising granulated substance of barley young leaf |
DK1498039T3 (en) * | 2002-03-29 | 2012-10-15 | Frente Internat Co Ltd | Vital cell preparations containing lactic acid bacteria as active substance and lactic acid bacteria containing food products |
US20050281756A1 (en) * | 2004-06-14 | 2005-12-22 | Eamonn Connolly | Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation |
US6872565B2 (en) * | 2003-01-29 | 2005-03-29 | Biogaia Ab | Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries |
KR100845034B1 (en) * | 2006-08-31 | 2008-07-08 | 경북대학교 산학협력단 | Antibacterial activity of lactobacillus sp. knuc25 isolated from kimchi |
EP2133414A1 (en) * | 2008-06-11 | 2009-12-16 | Basf Se | Uses and methods for preventing and /or treating oral malodour |
EP2420580A1 (en) * | 2010-08-18 | 2012-02-22 | AB-Biotics, S.A. | Probiotic composition for oral health |
MX343566B (en) * | 2010-08-31 | 2016-11-09 | Centro Superior De Investig En Salud Publica (Csisp) * | Anticaries compositions and probiotics/prebiotics. |
JP5881017B2 (en) * | 2010-11-05 | 2016-03-09 | 国立大学法人広島大学 | Plant lactic acid bacteria isolated from rice husk or brown rice and use thereof |
EP2667883A1 (en) * | 2011-01-24 | 2013-12-04 | Basf Se | Oral health improving compositions |
CN104023732B (en) * | 2011-08-05 | 2017-09-01 | 株式会社养乐多本社 | The prevention of oral disease or therapeutic agent |
CN108795734A (en) * | 2018-03-16 | 2018-11-13 | 孙百莉 | A kind of lactic acid bacteria detecting system and preparation method thereof |
CN113005055B (en) * | 2021-02-08 | 2022-06-17 | 无限极(中国)有限公司 | Lactobacillus plantarum for preventing and/or treating periodontitis, culture thereof, and preparation and application thereof |
KR102630612B1 (en) * | 2021-02-10 | 2024-01-31 | 숙명여자대학교산학협력단 | Food Composition for Preventing or Improving Oral Disease or Colorectal Disease, Comprising a new Enterococcus faecalis strain and its whey fermentation product |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2355508B1 (en) * | 1976-06-21 | 1978-11-17 | Inst Rech Scient Irs | MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF DENTAL CARIES AND PERIODONTOPATHIES AND ITS PREPARATION METHOD |
EP0154549B1 (en) * | 1984-03-09 | 1990-12-27 | Kabushiki Kaisya Advance | Anticariogenic or antiperiodontitic agent |
JPH054927A (en) * | 1991-06-28 | 1993-01-14 | Aizo Matsushiro | Lactic acid-containing composition and production thereof |
-
1998
- 1998-01-07 KR KR19980000213A patent/KR100266752B1/en not_active IP Right Cessation
- 1998-07-02 CN CN98807912A patent/CN1268172A/en active Pending
- 1998-07-02 TR TR2000/00360T patent/TR200000360T2/en unknown
- 1998-07-02 BR BR9814737-4A patent/BR9814737A/en not_active IP Right Cessation
- 1998-07-02 MX MXPA00001347 patent/MXPA00001347A/en unknown
- 1998-07-02 IL IL13441098A patent/IL134410A0/en unknown
- 1998-07-02 EP EP98931104A patent/EP1002052A1/en not_active Withdrawn
- 1998-07-02 WO PCT/KR1998/000191 patent/WO1999007826A1/en not_active Application Discontinuation
- 1998-07-02 AU AU81312/98A patent/AU752706B2/en not_active Ceased
- 1998-07-02 JP JP2000506311A patent/JP2001512670A/en active Pending
- 1998-07-02 CA CA002299627A patent/CA2299627A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU8131298A (en) | 1999-03-01 |
MXPA00001347A (en) | 2002-03-01 |
TR200000360T2 (en) | 2000-07-21 |
BR9814737A (en) | 2000-10-03 |
AU752706B2 (en) | 2002-09-26 |
EP1002052A1 (en) | 2000-05-24 |
WO1999007826A1 (en) | 1999-02-18 |
CN1268172A (en) | 2000-09-27 |
JP2001512670A (en) | 2001-08-28 |
KR100266752B1 (en) | 2001-03-02 |
KR19990023039A (en) | 1999-03-25 |
IL134410A0 (en) | 2001-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU752706B2 (en) | Novel lactic acid bacteria | |
US6036952A (en) | Lactic acid bacteria inhibiting the formation of dental plaque in the mouth | |
US20050158254A1 (en) | Use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries | |
US20050186148A1 (en) | Incorporation of exogenous lactic bacteria into the oral microflora | |
US7250162B2 (en) | Lactic acid bacteria inhibiting halitosis | |
JP2015006185A (en) | Means and methods for preventing and/or treating caries | |
EP0154549A2 (en) | Anticariogenic or antiperiodontitic agent | |
US9226517B2 (en) | Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells | |
JP4846643B2 (en) | New lactic acid bacteria | |
US20050271640A1 (en) | Method for inhibiting yeast growth | |
US20030077814A1 (en) | Novel lactic acid bacteria | |
KR900001433B1 (en) | Process for manufacturing beverage and composition to prevent human dental caries | |
KR19990086509A (en) | Lactobacillus inhibits anaerobic bacteria in human oral cavity | |
KR20060043665A (en) | Lactic acid bacteria inhibiting halitosis | |
JPH03251171A (en) | Production of noncariogenic microorganism and noncariogenic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |